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Osteoblast differentiationTransforming growth factor β (TGFβ) is known to play important roles in multiple developmental processes.
One of the main functions is in skeletal development. Our previous studies demonstrated that loss of Tgfbr2
in Prx1Cre-expressing limb mesenchyme results in defects in the long bones and joints of mice. Here we
show that loss of Tgfbr2 also results in defects in the development of the skull vault indicating Tgfbr2 has a
critical role in intramembranous bone formation as well as endochondral bone formation. Mutant mice did
not survive after birth and demonstrated an open skull. The ﬁrst signs of skull defects were observed at E14.5
day. Prx1Cre+/Tgfbr2f/f embryos showed signiﬁcantly reduced cell proliferation in the developing
mesenchyme of the skull by E14.5 day without any detectable alteration in apoptosis suggesting that
reduced cell proliferation in Prx1Cre+/Tgfbr2f/f embryos was at least partially responsible for the defects
observed. Immunoﬂuorescent staining showed a signiﬁcant reduction in the expression of Runx2/Cbfa1 and
Osterix/Sp7 in Prx1Cre+/Tgfbr2f/f embryos suggesting that osteoblast differentiation was also altered in
Prx1Cre+/Tgfbr2f/f embryos. To distinguish between the effects of losing Tgfbr2 on mesenchymal
proliferation versus osteoblast differentiation, osteoprogenitor cells from the skulls of Tgfbr2f/f embryos
were cultured under conditions of high cell density and Tgfbr2 was deleted from the cells using Adeno-Cre
virus. RT-PCR analysis showed that the mRNA level of Runx2 and Osterix as well as Dlx5 and Msx2 were
down-regulated in Tgfbr2-deleted cultures compared to control cultures indicating that Tgfbr2 regulates
osteoblast differentiation independent of regulating proliferation. Together, these results suggest that Tgfbr2
is required for normal development of the skull.
© 2009 Elsevier Inc. All rights reserved.Introduction
The murine skull vault consists of mainly two different skeletal
elements, the frontal and parietal bones. Each component is formed
from entirely different tissue origins during development, cranial
neural crest (CNC) or cephalic mesoderm, respectively (Jiang et al.,
2002). Previous studies using transgenic mouse models have
demonstrated that CNC contributes to the formation of the frontal
bone but not the parietal bone during embryonic development (Jiang
et al., 2002; Tyler, 1983). The parietal bone is derived from cephalic
mesoderm and both the frontal and parietal bone are formed by
intramembranous bone formation. Despite the fact that the parietal
bone occupies a large portion of the skull vault, most studies have
been focused on the mechanism of CNC derived craniofacial bone
development (Han et al., 2007; Ishii et al., 2003; Sasaki et al., 2006). In
this study, we address the cell autonomous roles of Tgfbr2 in
development of the skull vault.
Intramembranous bone formation is a series of events covering
the commitment of mesenchymal cells to the osteoblast lineage, to
maturation of osteoblast characterized by deposition of mineralizedll rights reserved.bone matrix. Each step for osteoblast differentiation is strictly regu-
lated by several transcription factors (Franceschi et al., 2008;
Karsenty and Wagner, 2002; Marie, 2008). Runx2/Cbfa1 has been
identiﬁed as one of the major transcription factors responsible for
osteoblast differentiation. It is expressed as mesenchymal cells are
committed to the osteoblast lineage and throughout the differenti-
ation process. Runx2/Cbfa1 mutant mice showed arrested osteoblast
differentiation in all developing skeletal elements (Komori et al.,
1997). Another key molecule, Osterix/Sp7, is a zinc ﬁnger transcrip-
tion factor exclusively expressed in osteoblasts that acts down-
stream of Runx2/Cbfa1 during skeletal development (Celil et al.,
2005; Nakashima et al., 2002). In Osterix null mutant mice, endo-
chondral and intramembranous bone formation were affected, but
the failure of osteoblast differentiation occurred at a later step than
in Runx2/Cbfa1 null mice. Several growth factors such as TGFβ1
and BMP2 are known to regulate expression of these transcription
factors. TGFβ1 and BMP2 treatment promoted Runx2/Cbfa1 ex-
pression in osteoblast cell lines (Hay et al., 2004; Lee et al., 2000)
and Tgfbr2 deletion in CNC derived frontal bone primodium resulted
in a decrease in Runx2/Cbfa1 and Osterix/Sp7 expression (Sasaki et
al., 2006).
TGFβ is a member of the highly conserved TGFβ/BMP family of
multi-functional peptides. Eachmember in this family is a structurally
similar peptide that regulates multiple aspects of development such
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cellular matrix (Dunker and Krieglstein, 2000; Ito et al., 2003;
Kingsley, 1994; Mummery, 2001; Serra and Chang, 2003; Verrecchia
and Mauviel, 2002). TGFβ ligands initiate signaling pathways via
binding to their receptor, TGFβRII, which is a constitutively active
serine/threonine kinase. Binding of the ligands to TGFβRII triggers
formation of a heterotetrameric complex consisting of two TGFβRII
and two TGFβ type I receptors (TGFβRI). The formation of the com-
plex enables TGFβRII to phosphorylate TGFβRI resulting in activation
of TGFβRI. Activated TGFβRI phosphorylates downstream mole-
cules, Smad2/3, which results in complex formation with Smad4.
Consequently, the Smad complex translocates into nucleus and
induces cellular responses as a result of Smad transcriptional regu-
latory activity.
Recent studies using transgenic mouse models demonstrated the
signiﬁcance of TGFβ signaling in the formation of skull. Mice with
germline deletion of the ligand Tgfb2 showed mild defects in bone
size and ossiﬁcation in frontal, interparietal, parietal, and squamosal
bones at E18.5 day (Sanford et al., 1997). TGFβ2/3 double knockout
mice demonstrated signiﬁcantly reduced frontal and parietal bones
at E15.5 day, suggesting that TGFβ ligands are functionally redun-
dant in skull development (Dunker and Krieglstein, 2002). Condi-
tional inactivation of Tgfbr2 in Wnt1Cre expressing CNC cells
revealed signiﬁcant defects in development of the frontal bone as
well as the parietal bone. Since Wnt1Cre is not expressed in the
parietal bone, it was suggested that paracrine effect of TGFβ was at
work in the developing skull. Wnt1Cre is active in the meninges
underlying the developing skull and it was suggested that the
interaction of the meninges with the parietal bone was critical for
normal development (Ito et al., 2003; Sasaki et al., 2006). This result
led us to investigate the cell autonomous functions of TGFβ signaling
in the developing skull. To examine the cell autonomous effects of
Tgfbr2 in parietal bone development, we speciﬁcally deleted Tgfbr2
in mesenchymal cells within the presumptive parietal and frontal
bones using Prx1Cre mediated recombination. Prx1Cre+/Tgfbr2f/f
mice were dead at birth showing severe defects in frontal and
parietal bones. The ﬁrst sign of skull defects in mutant embryos was
detected at E14.5 day by H&E staining. The failure of frontal and
parietal bone formation in mutant embryos was shown to be
primarily the result of reduced mesenchymal proliferation. Marker
analysis also showed alterations in expression of Runx2/Cbfa1 and
Osterix/Sp7. Generally, normal development of the skeletal ele-
ments during embryogenesis requires a certain level of cell density
as well as signals directing their differentiation. Missing either
one can result in the failure of normal development. To deter-
mine whether the alterations in osteogenic marker expression in
Prx1Cre+/Tgfbr2f/f embryos were an independent effect of the loss
of Tgfbr2 or whether a consequence of decreased osteoprogenitor
cell proliferation, we examined the expression of osteoblast markers
in Tgfbr2f/f cells treated with Ad-Cre or Ad-EGFP virus in cultures
under conditions of high cell density. The mRNA levels of Runx2/
Cbfa1 and Osterix/Sp7 were down-regulated in Ad-Cre-treated
cultures compared to Ad-EGFP-treated control cells indicating that
the requirement of Tgfbr2 for osteoblast differentiation is indepen-
dent of proliferation and cell density. Together, our results suggest
that Tgfbr2 is required for normal development of the skull and acts




Mice in which exon2 of Tgfbr2 was ﬂanked with loxP sites
(Tgfbr2f/f) were obtained from Dr. H.L Moses, Vanderbilt University,
Nasshville, TN (Chytil et al., 2002). Tgfbr2f/f mice were crossed totransgenic mice that express Cre under the control of the Prx1
promoter (obtained from Dr. Clifford J. Tabin, Harvard Medical
School, Boston, Massachusetts) (Logan et al., 2002) to create a
mouse in which Tgfbr2 was deleted in calvarial osteoprogenitors.
The genotype of adult transgenic mice and embryos was determined
by PCR analysis as previously described (Bafﬁ et al., 2004; Seo and
Serra, 2007).
Semi-quantitative RT-PCR analysis
RNA was isolated from calvarial osteoprogenitors from E14.5 day
embryos and cultured cells using the standard Trizol method. mRNA
concentration was measured by ND-1000 UV spectrophotometry
(Nanodrop). For semi-quantitative RT-PCR analysis, cDNA was
synthesized from 2.5 μg of total mRNA using random primers and
20–100 ng of cDNA template was ampliﬁed for 20, 25 and 30 or 25,
30 and 35 cycles. PCR was performed using the following primers:
Runx2/Cbfa1 primers (forward 5′-TCA TGG CCG GGA ATG ATG AGA
ACT-3′ and reverse 5′-AGC TTC TGT CTG TGC CTT CTT GGT-3′),
Osterix/Sp7 (forward 5′-TCC CTT CTC AAG CAC CAA TGG ACT-3′,
reverse 5′-AAG TGT AGA CAC TAG GCA GGC AGT-3′), Dlx5 primers
(forward 5′-TAG GAC TGA CGC AAA CAC AGG TGA-3′ and reverse
5′-GAA TTG ATT GAG CTG GCT GCG CTT-3′), Msx2 primers (forward
5′-TTC TCC GAC TAA AGG CGG TGA CTT-3′ and reverse 5′-TCC GGT
TGG TCT TGT GTT TCC TCA-3′), Tgfbr2 exon2 primers (forward 5′-
TTA ACA GTG ATG TCA TGG CCA GCG-3′ and reverse 5′- AGA CTT
CAT GCG GCT TCT CAC AGA-3′), 18S primers (forward 5′-ACG GGA
GGG CAC CAC CAG G-3′, reverse 5′-CAC CAA CTA AGA ACG GCC ATG
C-3′), Histone H4b primers (forward 5′-ACA ACA TCC AGG GCA TCA
CCA A-3′, reverse 5′-TTG AGC GCG TAG ACC ACG TCC AT-3′). Fold
difference in expression level was calculated based on band
intensity using histogram in Photoshop software. Pixel densities of
three sets of each gene were measured, and mean value was
calculated and normalized with 18S. The efﬁciency of DNA ampli-
ﬁcation was determined by varying the number of cycles for each
primer pair. Results are shown in the linear range of product
formation.
Skeletal staining
To investigate the skeletal structure in developing skull vault,
E15.5 and 18.5 day embryos were double-stained for bone and cartil-
age with Alizarin red and Alcian blue (Kimmel and Trammell, 1981;
McLeod, 1980). Staining was performed as previously described (Seo
and Serra, 2007). Images were captured using an Olympus SZ12
stereo-microscope and magnaﬁre digital camera.
Histology
Female mice at E13.5, E14.5, E15.5, and E16.5 days gestation were
dissected for embryos. Noon on the day of the vaginal plug is E0.5 day.
Embryos were ﬁxed in 4% paraformaldehyde at room temperature for
2 h, dehydrated in ethanol solution and embedded in parafﬁn.
Sections were cut at a thickness of 5–6 μm andmounted on Superfrost
Plus slides (Fisher). For histological analysis, sections were stained
with hematoxylin and eosin (H&E). For Prx1Cre+/R26R reporter
mice, embryos at E13.5 and 15.5 were ﬁxed in 4% paraformaldehyde
for 30 min at 4 °C and permeabilized in permeabilization solution
(2 mMMgCl2, 0.01% NaDeoxycholate, 0.02% NP-40 in PBS) for 10 min
at room temperature twice. Following permeabilization, embryos
were incubated in X-gal staining solution (2 mM MgCl2, 5 mM K
ferncyanide, 5mMK ferrocynaide, 1 mg/ml X-Gal in PBS) overnight at
room temperature. After post-ﬁxation, embryos were sectioned as
described above. Sections were dewaxed and mounted. Images were
captured with an Olympus BX-51 ﬂuorescent microscope and macro-
ﬁre digital camera.
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To examine mineralization, sections from E15.5 embryos were
incubated in 1% silver nitrate for 30 min while under sun light.
Unreacted silver was washed with 5% sodium thiosulfate and distilled
water for 5 min each. Sections were dehydrated and coverslipped
using permanent mounting medium.
Immunoﬂuorescence staining
Prepared sections were incubated with rabbit anti-Osterix/Sp7
antibody (Abcam, diluted 1:200) as a primary antibody and goat
biotinylated anti-rabbit IgG as a secondary antibody. Fluorescent
signal was detected with Avidin-conjugated Cy3 and sections were
counterstained with DAPI or Yopro. For Runx2/Cbfa1 staining, M.O.M
kit (Vector) was used according to the manufacturer's instruc-
tions with mouse anti-Runx2 antibody (MBL, diluted 1:200) as a
primary antibody. Slides were mounted with Aqua poly/Mount
(Polyscience Inc.).
Cell proliferation and TUNEL labeling
Cell proliferation was measured by BrdU staining. 60 μg/g (BrdU/
body weight) of BrdU was injected intraperitoneally into the female
mice at 13.5 and 14.5 days gestation 1 h before sacriﬁce and removal
of embryos. Rat monoclonal anti-BrdU antibody (Abcam) was used as
described above for immunoﬂuorescence staining. For TUNEL stain-
ing, TdT-Frag EL™ Fragmentation Detection Kit (Calbiochem) was
used according to the manufacturer's instructions.
Osteoblast culture
Calvarial tissue containing osteoprogenitors were dissected and
separated from Tgfbr2f/f embryos at E14.5 day. Separated tissue
was dissociated into a single cell suspension with incubation with
1 mg/ml of collagenase D and 0.1% trypin EDTA in DPBS for 30 min at
37 °C. 5×106 cells were plated to a 6 well plate and pre-incubated in
growth medium for 3 days at 37 °C in CO2 incubator. After pre-
incubation allowing cells to reach conﬂuence, the cells were
incubated with Adeno-Cre-EGFP virus to remove Tgfbr2 and with
Adeno-EGFP virus as a control. After 24 h, cells were fed with
differentiation medium (MEM containing 10 % FBS, 50 μg/ml ascorbic
acid, 10 mM β-glycerolphosphate, 2 mM glutamine, antibiotics). Cells
were incubated at 37 °C in CO2 incubator for another 3 days. Medium
was replaced every 2 days. Following incubation, mRNA was isolated
for further RT-PCR analysis as described above.
Results
Deletion of Tgfbr2 in the developing skull
The frontal and parietal bones are major components of the skull
vault covering medial and lateral aspect of the brain. They are
formed by intramembranous bone formation in which mesenchymal
cells directly differentiate into osteoblasts. Previously, it was shown
that loss of Tgfbr2 in the meninges, which is derived from CNC,
results in defects in development of the parietal bone suggesting
paracrine effects of TGFβ (Sanford et al., 1997; Sasaki et al., 2006). To
determine if TGFβ signaling is also required in a cell autonomous
manner for normal development of the parietal bone, Tgfbr2 was
deleted by Cre mediated recombination in the skull using Prx1Cre as
previously described (Seo and Serra, 2007). To determine the exact
location of Prx1Cre recombinase activity in the developing skull,
Prx1Cre+ mice were crossed with R26R reporter mice, and embryos
at E13.5 and 15.5 day were stained by X-gal and sectioned for further
analysis (Figs. 1B–G). Sagittal sections of E13.5 day Prx1Cre/R26Rembryos showed strong X-gal staining in the mesenchymal cells
covering the entire developing brain from anterior of the presump-
tive frontal bone to posterior of the presumptive parietal bone
(Figs. 1B–D). In E15.5 embryos, Cre recombinase activity was limited
to the dermis and the osteoprogenitor layer in both presumptive
frontal and parietal areas (Figs. 1E–G). Activity was not detected in
the skin or the meninges, which are derived from ectoderm (Ito
et al., 2003; Jiang et al., 2002). Deletion of Tgfbr2 was conﬁrmed by
RT-PCR (Fig. 1A). For RT-PCR analysis, mRNA was isolated from the
tissue between the skin and brain of Cre− control and Prx1Cre+/
Tgfbr2f/f embryos at E14.5 day. The results showed a signiﬁcant
reduction in the level of Tgfbr2 mRNA in Prx1Cre+/Tgfbr2f/f em-
bryos compared to control embryos, indicating that Tgfbr2 in the
developing skull was effectively removed. These results conﬁrm
that Tgfbr2 is effectively deleted in the osteoprogenitor cell layer
within the presumptive frontal and parietal bones by Cre-mediated
recombination and that the meninges is not targeted by Prx1-Cre.
Conditional inactivation of Tgfbr2 in calvarial osteoprogenitor cells
results in the failure of normal skull development
To further determine if there were any cell-autonomous require-
ments for Tgfbr2 in the formation of the parietal bone, heads from
E15.5 and E18.5 day Prx1Cre+/Tgfbr2f/f embryos were stained with
Alcian blue and Alizarin red (Fig. 2). In the Prx1Cre+/Tgfbr2f/f
embryos, most of the parietal bone and frontal bone were missing,
and the interparietal bone was slightly reduced in size (Figs. 2B–G).
Bones in the base of the skull developed normally in Prx1Cre+/
Tgfbr2f/f embryos (Figs. 2D–G). This was expected since Prx1Cre is not
expressed in these bones. This result suggests that Tgfbr2 is required
in a cell-autonomousmanner for intramembranous bone formation in
the frontal and parietal bones.
H&E staining of transverse sections from Prx1Cre+/Tgfbr2f/f
embryos showed more details of the defects (Fig. 3). The black and
white lines in Fig. 3A show the location of the transverse sections
revealing the lateral aspect of the skull (Figs. 3B–K), and the loca-
tion of the sagittal sections revealing the medial aspect of the skull
(Figs. 3L–O). The thickness of the osteoprogenitor cell layer in
mutant embryos was similar to control embryos at E13.5 days (Figs.
3B, C, brackets). However, the thickness of this layer in both
presumptive frontal and parietal bones was slightly reduced at
E14.5 day (not shown) and signiﬁcantly reduced after E15.5 day in
Prx1Cre+/Tgfbr2f/f embryos relative to controls (Figs. 3D–G, lower
brackets). In E15.5 day control embryos, we were able to see
mineralization along the entire skull, but little to no mineralization
was observed in Prx1Cre+/Tgfbr2f/f embryos (Figs. 3H–K, arrow-
heads). Formation of the epidermis of the skin, and meninges in
E15.5 day mutant embryos were similar to control embryos but the
size of the dermis layer was also signiﬁcantly reduced in the
mutant embryos (Figs. 3D–G upper brackets). Midsagittal sections
of E16.5 day Prx1Cre+/Tgfbr2f/f embryos showed more signiﬁcant
reduction in the size of frontal and parietal bones compared to
control embryos (Figs. 3L–O) and there was no detectable mine-
ralization (not shown). The reduction in size and cell density of the
mesenchymal layers suggested that cell proliferation could be
responsible for the failure of the formation of the skull vault in
Prx1Cre−/Tgfbr2f/f embryos.
Loss of Tgfbr2 results in a decrease in cell proliferation but does not alter
cell survival in the developing parietal bone
To examine the mechanism responsible for the failure of skull
development, we compared the level of cell proliferation and apop-
tosis in the presumptive parietal bone from Prx1Cre+/Tgfbr2f/f
and Cre− control embryos at E13.5 and E14.5 days. Cell prolife-
ration was measured as the percentage of cells that incorporated
Fig. 1. Tissue-speciﬁc deletion of Tgfbr2. (A) To analyze deletion of Tgfbr2, mRNA was isolated from the developing skull mesenchyme of E14.5 Prx1Cre−/Tgfbr2f/w (−; f/w), and
Prx1Cre+/Tgfbr2f/f (+; f/f) embryos. Relative levels of Tgfbr2 mRNA were determined using RT-PCR. Primers recognizing sequences within exon2 were used. The level of Tgfbr2
mRNA was signiﬁcantly reduced in Prx1Cre+/Tgfbr2f/f embryos compared to Cre− control embryos. Product formation is shown within the linear range. Expression of β2-
microglobulin was used as a normalization control. (B–G) Prx1Cre recombinase activity was examined by X-gal staining in E13.5 (B–D) and 15.5 day embryos (E–G). Sagittal sections
from E13.5 day Prx1Cre+/R26R embryos show strong Cre activity in the developing skull. In E15.5 day embryos, Cre activity was detected within differentiating osteoprogenitor cells
(o) and in the dermis (d) in both frontal (F) and parietal (G) bones. Activity was not detected in the epidermis of the skin (s) or meninges (m) suggesting tissue-speciﬁc deletion of
Tgfbr2 in Prx1Cre+/Tgfbr2f/f embryos at these stages. fr=presumptive frontal bone, pa=presumptive parietal bone, br=brain.
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aspect to the dorsal aspect of the skull, we examined proliferation at
both sides of the skull using transverse sections (Figs. 4A, C, D, F) of
E13.5 and E14.5 day embryos, and the top of the skull using
midsagittal sections (Figs. 4B, E) of E13.5 day embryos. At E13.5 day,
the percentage of BrdU positive cells in the lateral aspects of E13.5
day Prx1Cre+/Tgfbr2f/f skull was reduced when compared with
control embryos, but it was not determined to be statistically
signiﬁcant (Figs. 3A, D, G). However, a signiﬁcant reduction in the
percentage of proliferating cells was detected in the medial aspects
of the parietal bone at this stage (Figs. 3B, E, H). At E14.5 day, there
was signiﬁcantly reduced cell proliferation within the lateral aspect
of the parietal bone in the Prx1Cre+/Tgfbr2f/f embryos (Figs. 3C, F,
I). The same pattern of cell proliferation was detected in the pre-
sumptive frontal bone of mutant and control embryos at E13.5 and
E14.5 days (data not shown). This result suggests that reduced cell
proliferation in skull mesenchyme is one of the factors responsible
for the failure of skull bone development in Prx1Cre+/Tgfbr2f/f
embryos.
To determine whether alterations in apoptosis contributed to
the disruption of skull development, we measured apoptosis in
cells of the developing parietal bone in Prx1Cre+/Tgfbr2f/f andcontrol embryos at E13.5 and E14.5 day using TUNEL analysis.
TUNEL-stained cells were not detected in either Cre− controls or
Prx1Cre+/Tgfbr2f/f embryos, indicating that excessive apoptosis in
Prx1Cre+/Tgfbr2f/f embryos is not responsible for the failure of skull
development (Figs. 3J–O). DNase I-treated sections from an E13.5
and E14.5 day Cre− control embryo skulls were used as positive
controls (Figs. 3J, M).
Deletion of Tgfbr2 results in reduced expression of osteoblast markers
To test whether the defects in skull bone development were also
due to alterations in osteoblast differentiation, we examined the
expression of Runx2/Cbfa1 and Osterix/Sp7 in Prx1Cre+/Tgfbr2f/f
and control embryos at E13.5, E14.5 and E15.5 days (Fig. 5). Runx2/
Cbfa1 is a key transcription factor for osteoblast differentiation
(Komori et al., 1997; Otto et al., 1997). Normal Runx2 expression
was detected in lateral aspects of E13.5 and E14.5 day control
embryos, and in the medial roof of E15.5 day control embryos (Figs.
5A, C, E). E13.5 day Prx1Cre+/Tgfbr2f/f embryos showed a similar
expression pattern with control embryos (Fig. 5B). However, starting
from E14.5 day, Runx2/Cbfa1 expression was not detected in either
lateral or medial aspect of the developing parietal bone (Figs. 5D, F). It
Fig. 2. Skull defects in Prx1Cre+/Tgfbr2f/f embryo. (A) Prx1Cre+/Tgfbr2f/f (left) mice were born without a skull vault. Prx1Cre- control is on the right. (B–G) Alcian blue and Alizarin
red staining shows details of skull defects in Prx1Cre+/Tgfbr2f/f (C, E, G) and Prx1Cre-negative control embryos (B, D, F) at E15.5 days (B, C) and E18.5 days (D–G). At E15.5, control
embryos (B) show distinctive frontal, parietal bone and sutural area which are not detected in Prx1Cre+/Tgfbr2f/f embryos (C). At E18.5, skeletal staining of control embryos show
well developed frontal and parietal bone as well as base of skull (D, F). In Prx1Cre+/Tgfbr2f/f embryos, most of frontal and parietal bone are absent, but base of skull shows normal
development compared to control embryos (E, G). (fr, frontal bone; pa, parietal bone; su, suture; ip, interparietal bone; na, nasal; oc, occipital bone; mx, maxilla; ma, mandible; zy,
zygomatic; sq, squamosal).
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and upregulates expression of osteoblast marker genes (Celil et al.,
2005; Fu et al., 2007; Nakashima et al., 2002). The expression of
Osterix/Sp7 showed the same expression pattern of Runx2/Cbfa1
(Figs. 5G–L). Osterix/Sp7 expression was comparable in control and
mutant embryos at E13.5, but it was not detected in E14.5 and E15.5
day mutant embryos compared to control embryos. This result
suggests that loss of Tgfbr2 also affects differentiation of osteoblasts.
However, it is not clear if this is a direct effect on differentiation or a
consequence of reduced cellular proliferation.Tgfbr2 is required for osteoblast differentiation independent of effects on
cell proliferation
Mesenchymal condensation is known to be required for the
initiation of intramembranous bone formation during skeletal
development. Low cell density leads to the failure of cell condensa-
tion, which can consequently result in defects in skeletal develop-
ment, suggesting that a certain level of cell density is required for the
initiation of differentiation. Since we showed a decrease in prolifer-
ation of themesenchyme in the presumptive skull bones of Prx1Cre+/
Fig. 3.Histological analysis of skull defects in Prx1Cre+/Tgfbr2f/f embryos. (A) Black and white lines indicate the sectioned area of skull. Sagittal sections show the medial aspect and
transverse sections show the lateral aspect of the skull. Transverse (B–K) and sagittal (L–O) sections of developing skull from Prx1Cre+/Tgfbr2f/f (C, E, G, I , K, M, O) and control
embryos (B, D, F, H, J, L, N) were stained with H&E for histological analysis (A-–G, L–O) or von Kossa to visualize mineral (H-K). At E13.5 day, the lateral aspect of the presumptive
parietal bone in Prx1Cre+/Tgfbr2f/f (B, brackets) and control embryos (C, brackets) demonstrate similar thickness. E15.5 day Prx1Cre+/Tgfbr2f/f embryos showed a signiﬁcant
reduction in thickness (fr, pa, brackets) and mineralization (arrowheads) in frontal and parietal bone compared to control embryos (D-K). At E16.5 day, Prx1Cre+/Tgfbr2f/f embryos
(M,O, arrowhead) demonstrated reduced thickness in presumptive frontal and parietal bones compared to control embryos (L, N, arrowhead). (fr, frontal bone; pa, parietal bone;
m, meninges; ep, epidermis; d, dermis).
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expression of osteoblast markers is due to the loss of Tgfbr2 directly
or if it is a consequence of reduced cell proliferation and reduced cell
density. To this end, we examined expression of osteoblast markers in
cells with deletion of Tgfbr2 cultured under conditions of high cell
density. To accomplish both the deletion of Tgfbr2 and high cell
density, skull mesenchyme from E14.5 day Tgfbr2f/f embryos was
plated at 70% density and allowed to grow for 3 days to reach
conﬂuence before deletion of Tgfbr2. At conﬂuence, Ad-Cre or Ad-
EGFP virus, as a control, was added to the cultures to remove Tgfbr2.
Three days after virus treatment, mRNA was isolated for RT-PCR
analysis (Fig. 6). There were no alterations in the morphology of the
cells over the time course of the experiment (Fig. 6A). Ad-Cre-infected
cells showed signiﬁcant loss of Tgfbr2 mRNA (Fig. 6B). In Ad-Cre-
infected cultures, mRNA levels of Runx2/Cbfa1 and Osterix/Sp7 were
signiﬁcantly decreased even under the condition of high cell density
when compared to Ad-EGFP-infected or uninfected controls (Fig. 6C).
Furthermore, Dlx5 and Msx2 expression were signiﬁcantly down-
regulated in Ad-Cre-infected culture compared to Ad-EGFP-infected
and uninfected control cells (Fig. 6C). Dlx5 is known as an essential
transcription factor for the differentiation of calvarial osteoblasts.
Dlx5 mutant mice demonstrated delayed skull ossiﬁcation (Acampora
et al., 1999; Robledo et al., 2002). Moreover, over-expression of Dlx5
induced Runx2/Cbfa1 expression in chick mesenchyme in vitro
(Holleville et al., 2007). It was also shown that Msx2 is expressed inthe developing parietal bone and Msx1/2 double knockout mice
display severe defects in skull formation (Han et al., 2007; Ishii et al.,
2003; Satokata et al., 2000). Histone H4b primers were used to test for
differences in cell proliferation (Holmes et al. 2005). Expression of
histone H4b in Ad-Cre-infected cells was comparable to both Ad-
EGFP-infected and uninfected control cells (Fig. 6C) suggesting
proliferation was not affected by deletion of Tgfbr2 in the conﬂuent
cultures. Similar results were seen in three separate experiments.
Together, these results suggest that alterations in proliferation and
differentiation in Tgfbr2-deleted mesenchyme are independent
effects.
Discussion
The vertebrate skeleton is produced from three embryonic line-
ages. The appendicular skeleton is formed by lateral plate mesoderm,
the axial skeleton is derived from paraxial mesoderm, and craniofacial
bones are derived from cephalic mesoderm and cranial neural crest,
which originates from ectoderm (Olsen et al., 2000). During skeletal
development, cells in these lineages migrate to their target location,
condense, and begin the differentiation processes to form skeletal
elements. There are two mechanisms for skeletal development:
endochondral bone formation and intramembranous bone formation.
These two processes can be distinguished by the cartilage model that
is formed during endochondral bone formation. In contrast to
Fig. 4. Reduced cell proliferation in presumptive skull bones. Immunostaining of BrdU-labeled osteoprogenitor cells in the developing parietal bone from E13.5 (A, B, D, E) and E14.5
(C, F) day control (A–C) and mutant (D–F) embryos. Specimens were immunostained using an anti-BrdU antibody (orange, arrows) and counterstained with YoPro (green). BrdU-
positive cells in skin and the brain were not counted. In the lateral aspects of the skull from E13.5 day embryos, percentages of proliferating cells were reduced but not statistically
signiﬁcant (A, D, G). Signiﬁcant reduction in the number of BrdU positive cells was detected in the medial aspect of E13.5 day (B, E, H) and lateral aspect of E14.5 day (C, F, I) mutant
embryos compared to control embryos. At E13.5 (J–L) and E14.5 (M–O) day, no apparent apoptotic activity was detected in either Prx1Cre+/Tgfbr2f/f (L, O) or control (K, N) embryos
indicating that the failure of skull development in Prx1Cre+/Tgfbr2f/f embryos was not due to an increase in apoptosis but a decrease in cell proliferation. TUNEL positive signals are
shown as green cells in the DNase I-treated positive control (J, M).
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Fig. 5. Expression of osteoblast markers was altered in Prx1Cre+/Tgfbr2f/f embryos. Expression of Runx2 and Osterix were examined in the presumptive parietal bone in E13.5
(A, B, G, H), E14.5 (C, D, I, J) and E15.5 (E, F, K, L) day embryos. Specimens were immunostained using an anti-Runx2 (A-F) and anti-Osterix antibodies (G-H) (orange, arrow)
and counterstained with YoPro (green). At E13.5 and E14.5 day, control embryos show expression of Runx2 and Osterix in lateral aspects of the skull (A, C, G, I, arrow). In E13.5
day Prx1Cre+/Tgfbr2f/f embryos (B, H), Runx2 and Osterix expression in lateral aspects of skull was comparable with control embryos (A, G), but a signiﬁcant reduction
of Runx2 and Osterix expression was detected in E14.5 day Prx1Cre+/Tgfbr2f/f embryos compared to control embryos (C, D, I, J, arrow). In E15.5 day Prx1Cre+/Tgfbr2f/f
embryos, there was no Runx2 and Osterix expression in the roof of the skull compared to control embryos (E, F, K, L, arrow) indicating altered osteoblast differentiation in
Prx1Cre+/Tgfbr2f/f embryos.
488 H.-S. Seo, R. Serra / Developmental Biology 334 (2009) 481–490endochondral bone formation, intramembranous bone formation is
a relatively simple mechanism. Mesenchymal cells condense and
directly differentiate into osteoblasts. Most studies of intramembra-
nous bone formation have focused on cranial neural crest lineages
(Iseki et al., 1999; Ishii et al., 2005, 2003; Ito et al., 2003; Sasaki et al.,
2006; Tyler, 1983). Previous cell tracing studies using Wnt1Cre/R26R
showed that cranial neural crest contributes to the frontal bone but
not the parietal bone (Chai et al., 2000). The meninges lying
underneath both the frontal and parietal bones is also derived from
cranial neural crest. Mice with conditional inactivation of Tgfbr2 using
Wnt1Cre demonstrated severe defects in the parietal bone as well as
the frontal bone even though Wnt1Cre is not expressed in precursors
of the parietal bone. It was suggested that TGF-β signaling in the
meninges was required for proper skull development (Ito et al., 2003;
Sasaki et al., 2006). To examine the cell autonomous effects of Tgfbr2
on development of the skull bones, we used Prx1Cre to delete Tgfbr2
in the developing skull mesenchyme. Mice carrying Prx1Cre recom-
binase were crossed to mice in which exon 2 of Tgfbr2 was ﬂanked
with loxP sites, resulting in conditional deletion of Tgfbr2 primarily in
limb mesenchyme and in the skull mesenchyme (Logan et al., 2002).
By E15.5 days, Prx1Cre activity was speciﬁcally detected in the dermis
and in the osteoprogenitor cell layer of the skull, but it was not
detected in epidermis or meninges. Skeletal staining of E15.5 and
E18.5 day embryos displayed severe defects in the skull vault
including a failure in the formation of both the frontal and parietalbones. The results suggest that in addition to the signals from the
meninges, Tgfbr2 can also act in a cell autonomousmanner to regulate
development of the skull bones.
Mice with a germline deletion of the TGFβ2 ligand as well as
TGFβ2/3 double knockout mice presented with defective frontal and
parietal bone development, which is consistent with our results
(Dunker and Krieglstein, 2002; Sanford et al., 1997). On the other
hand, in the Prx1Cre+/Tgfbr2f/f mice, the interparietal bone was only
slightly reduced just in the intramembranous portion but the
chondrogenic portion was not severely affected. Our previous study
showed normal initiation of chondrocyte differentiation in the limb
buds of Prx1Cre+/Tgfbr2f/f embryos (Seo and Serra, 2007). Mesen-
chymal condensation and the commitment to chondrocyte differen-
tiation in the limbs of E12.5 day Prx1Cre+/Tgfbr2f/f embryos were
normal. Likewise, loss of Tgfbr2 in the sclerotome did not affect
chondrocyte differentiation or expression of Sox9 (Bafﬁ et al., 2004,
Bafﬁ et al., 2006). These results again suggest that Tgfbr2 is not
required for the initiation of chondrogenesis, at least at the stages
under study.
In H&E staining of E14.5 and E15.5 day mutant and control
embryos, the size of the osteoprogenitor cell layer in Prx1Cre+/
Tgfbr2f/f embryos was reduced suggesting that cell proliferation was
decreased. As we expected, BrdU labeling assays demonstrated
signiﬁcantly decreased proliferation of cells in the presumptive
frontal and parietal bones of E13.5 mutant embryos, even though
Fig. 6. Tgfbr2 regulates differentiation of osteoblasts independent of effects on proliferation. Mesenchymal cells from E14.5 day Tgfbr2f/f skulls were cultured to conﬂuence thenwere
uninfected (con) or infected with Ad-EGFP (EGFP) or Ad-Cre (Cre) adenovirus. Three days after infection there was no signiﬁcant or consistent differences in the morphology of the
cells (A). RT-PCR analysis showed effective deletion of Tgfbr2 in Ad-Cre virus-treated culture (B). mRNAwas also isolated from cultured cells for semi-quantitative RT-PCR analysis of
osteoblast markers in cells with deletion of Tgfbr2 under conditions of high cell density (C). cDNA template was ampliﬁed for varying cycles number to ensure product formation in
the linear range. Results are shown for product formation with varying cycle number (triangle illustrates increasing cycle number). The levels of Runx2/Cbfa1, Osterix/Sp7, Dlx5,
Msx2 were signiﬁcantly down-regulated in Ad-Cre-infected cells compared to Ad-EGFP-infected and uninfected control cells (C). Histone H4b expression was similar in Ad-Cre and
Ad-EGFP-infected cells as well as in uninfected cells (C).
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studies using transgenic mice in which Tgfbr2 was removed from
various skeletal elements showed a signiﬁcant reduction in the
proliferation of chondrocytes, osteoprogenitor cells, and palatal
mesenchyme suggesting a primary function of Tgfbr2 in skeletal
development is in regulatingmesenchymal cell proliferation (Ito et al.,
2003; Sasaki et al., 2006; Seo and Serra, 2007). Intramembranous
bone formation also takes place in the bone collar of the long bones,
which is formed by cells in the periosteum surrounding the hyper-
trophic zone. The periosteum also displayed a signiﬁcant reduction in
size in Prx1Cre+/Tgfbr2f/f embryos suggesting that Tgfbr2 may also
be required for normal cell proliferation during formation of the bone
collar (Seo and Serra, 2007). It is likely that reduced thickness in the
dermis was also due to decreased mesenchymal cell proliferation and
that regulation of mesenchymal proliferation is a common biological
effect of TGF-β signaling in many tissues.
In addition to proliferation, E15.5 day mutant embryos showed
a signiﬁcant reduction in mineralization in the developing skull
indicating osteoblast differentiation was also affected in Prx1Cre+/
Tgfbr2f/f embryos. Marker analysis using immunoﬂuorescence
staining to examine osteoblast differentiation in mutant and
control embryos revealed that the level of Runx2/Cbfa1 and
Osterix/Sp7 protein, which are early markers of osteoblast
differentiation, were signiﬁcantly down-regulated in the mutant
embryos by E14.5 day indicating that osteoblast differentiation was
altered. Whether this was a direct effect of TGF-β on differentiationor a consequence of reduced cell proliferation was not immediately
clear. Intramembranous bone formation starts with the condensa-
tion of mesenchymal cells (Hall and Miyake, 2000). This condensed
population of cells grows and once they reach a critical level of cell
density, cells at the center of the condensation begin differentiation
into osteoblast. That is, without enough cell density, osteoblast
differentiation can fail. However, most previous studies using
transgenic mouse models to consider the role of TGF-β in skeletal
development concluded that loss of Tgbr2 is directly responsible
for alterations in osteoblast marker expressions without consider-
ing reduced cell density. To show that decreased marker expres-
sions in Prx1Cre+/Tgfbr2f/f embryos was not simply a consequence
of a failure of the mesenchyme to reach a critical density, we tested
for the expression of osteoblast markers in primary osteoprogeni-
tor cells grown in high-density culture in the presence or absence
of Tgfbr2. In culture, Tgfbr2 was removed using Ad-Cre after the
cells had reached conﬂuence. As a result, both Runx2/Cbfa1 and
Osterix/Sp7 expressions in Ad-Cre virus-infected cells was down-
regulated when compared to Ad-EGFP-infected and uninfected
control cells. Histone H4b, a marker of cell proliferation (Holmes et
al., 2005), was not altered by loss of Tgfbr2 in the conﬂuent
cultures. This result suggests that Tgfbr2 regulates osteoblast
differentiation and proliferation independently. In summary, the
results presented here provide information regarding signaling
though Tgfbr2 and the mechanisms of intramembranous bone
formation in mouse skull.
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